Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1NETWORK 1

Study Type

Observational 2Interventional 1

Sponsor

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

Immunoglobulins, Intravenous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Epilepsies, Partial × Clear all
NCT02890641 2026-04-17

GENEPHY

Fondation Ophtalmologique Adolphe de Rothschild

Recruiting
450 enrolled

Hypothalamic hamartomas, Focal Cortical Dysplasia, Encephalitis, Epilepsies, Partial, Tuberous Sclerosis, Hemimegalencephaly

NCT00001404 2019-12-16

Phenotype and Etiology of Pallister-Hall Syndrome

National Institutes of Health Clinical Center (CC)

Completed
1,170 enrolled

Hypothalamic hamartomas, Multiple Pterygium Syndrome, Autosomal Dominant, Abnormalities, Multiple, Epilepsies, Partial, Syndactyly, Polydactyly, Pallister-Hall Syndrome

NCT01545518 2014-09-01

IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Emory University

Phase 2 Terminated
20 enrolled 3 charts

Drug Resistant Epilepsy, Autoimmune Diseases, Epilepsy, Epilepsies, Partial, Autoimmune Diseases of the Nervous System, Limbic Encephalitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡